PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 16139453-3 2005 The stability-indicating HPLC method (C-8 column with a mobile phase of 52% 0.01 M pH 3.0 acetate buffer+48% acetonitrile) also enabled the study of perphenazine stability in solution under acidic, basic, oxidizing and photolysing conditions. Perphenazine 149-161 homeobox C8 Homo sapiens 38-41 16675366-10 2006 Older ("neuroleptic") antipsychotics, such as chlorpromazine, droperidol and haloperidol, perphenazine and many others, are likely to elevate serum prolactin. Perphenazine 90-102 prolactin Homo sapiens 148-157 16910628-7 2006 Similarly, antipsychotics such as perphenazine, chlorpromazine or haloperidol can increase antidepressant plasma levels, through the inhibition of CYP 450 isoenzymes (CYP2D6). Perphenazine 34-46 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 167-173 16156604-1 2005 A new helically pillared and chiral solid, Cu(pzc)2AgReO4 (I, pzc = pyrazinecarboxylate), was synthesized from hydrothermal reactions at 95-125 degrees C. The structural origin of its chirality, relative to the achiral M(pzc)2(H2O)2AgReO4 (II, M = Co; III, M = Ni) analogues, arises from significantly tilted pillars and hydrogen bonds to the AgReO4 layers. Perphenazine 46-49 mitochondrially encoded cytochrome c oxidase III Homo sapiens 248-255 16051556-6 2005 Therefore, we investigated the effects of four distinct phenothiazine drugs (thioridazine, chlorpromazine, trifluoperazine, and perphenazine) on hERG channel expressed in chinese hamster ovary (CHO) cells. Perphenazine 128-140 ETS transcription factor ERG Homo sapiens 145-149 16045015-4 2005 RESULTS: Perphenazine enhanced the expression of CD71 on K562 cells and increased Hb content in K562 cells, while inhibited the proliferation of K562 cells. Perphenazine 9-21 transferrin receptor Homo sapiens 49-53 16051556-8 2005 Thioridazine, perphenazine, trifluoperazine, and chlorpromazine blocked hERG potassium channels with the following IC(50) values: IC(50) values were 224 +/- 42 nM for thioridazine, 1003 +/- 71 nM for perphenazine, 1406 +/- 124 nM for trifluoperazine, and 1561 +/- 281 nM for chloropromazine. Perphenazine 200-212 ETS transcription factor ERG Homo sapiens 72-76 16051556-8 2005 Thioridazine, perphenazine, trifluoperazine, and chlorpromazine blocked hERG potassium channels with the following IC(50) values: IC(50) values were 224 +/- 42 nM for thioridazine, 1003 +/- 71 nM for perphenazine, 1406 +/- 124 nM for trifluoperazine, and 1561 +/- 281 nM for chloropromazine. Perphenazine 14-26 ETS transcription factor ERG Homo sapiens 72-76 12936703-9 2003 The IC50 values of typical substrates of CYP2D6 (bufuralol and dextromethorphan at lower substrate concentration) in inhibition studies using HLM, were similar to those in the case of recombinant CYP2D6, but the values of the compounds that are metabolized by multiple CYP forms (perphenazine and chlorpromazine) in HLM were much larger. Perphenazine 280-292 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 41-47 15122640-2 2004 We quantify the effect of replacing a hydrogen residue by a chlorine or a trifluoromethyl residue in position C-2 of promazine, perazine, and perphenazine analogues. Perphenazine 142-154 complement C2 Homo sapiens 110-113 12936703-9 2003 The IC50 values of typical substrates of CYP2D6 (bufuralol and dextromethorphan at lower substrate concentration) in inhibition studies using HLM, were similar to those in the case of recombinant CYP2D6, but the values of the compounds that are metabolized by multiple CYP forms (perphenazine and chlorpromazine) in HLM were much larger. Perphenazine 280-292 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 41-44 10770456-1 2000 The authors have previously reported that in elderly patients treated with low doses of perphenazine, few extrapyramidal symptoms (EPS) developed in those who were not poor CYP2D6 metabolizers. Perphenazine 88-100 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 173-179 12405639-1 2002 Maternal administration of perphenazine decreased the incidence of cannibalism in colonies of interferon-gamma, interleukin (IL-4, IL-10, and IL-12) knockout mice of the DBA/1 and C57BL/6 background strains. Perphenazine 27-39 interferon gamma Mus musculus 94-110 12405639-1 2002 Maternal administration of perphenazine decreased the incidence of cannibalism in colonies of interferon-gamma, interleukin (IL-4, IL-10, and IL-12) knockout mice of the DBA/1 and C57BL/6 background strains. Perphenazine 27-39 interleukin 10 Mus musculus 131-136 12083975-1 2002 Many antipsychotics, including perphenazine, zuclopenthixol, thioridazine, haloperidol and risperidone, are metabolised to a significant extent by the polymorphic cytochrome P450 (CYP) 2D6, which shows large interindividual variation in activity. Perphenazine 31-43 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 163-188 12083975-2 2002 Significant relationships between CYP2D6 genotype and steady-state concentrations have been reported for perphenazine, zuclopenthixol, risperidone and haloperidol when used in monotherapy. Perphenazine 105-117 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 34-40 11136295-7 2000 Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations. Perphenazine 115-127 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 11839208-6 2002 Interaction of [3H] pBR 322 DNA with chlorpromazine, perphenazine, and chloroquine was studied using these compounds as their free bases dissolved in chloroform, followed by their impregnation onto Whatman No. Perphenazine 53-65 translocator protein Homo sapiens 20-23 10460810-6 1999 No remarkable inhibition of other CYP isoforms was observed except for moderate inhibition of CYP1A2-catalyzed phenacetin O-deethylation by fluphenazine (K(i) = 40.2 microM) and perphenazine (K(i) = 65.1). Perphenazine 178-190 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 94-100 10688273-5 2000 Two studies failed to show that the CYP2D6 activity predicts the therapeutic effects of haloperidol or perphenazine. Perphenazine 103-115 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 36-42 10608490-9 1999 Although a relatively short period and small dose of administration might counteract the influence, trifluoperazine and perphenazine have less effect on CYP subfamilies than chlorpromazine or thioridazine. Perphenazine 120-132 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 153-156 9616188-1 1998 Classic antihistamines, namely diphenhydramine, chlorpheniramine, clemastine, perphenazine, hydroxyzine, and tripelennamine, share structural features with substrates and inhibitors of the polymorphic cytochrome P450 (CYP) isozyme CYP2D6. Perphenazine 78-90 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 201-216 18462031-2 1998 The serum PRL level was significantly decreased by danazol and increased by perphenazine compared to the intact and OVX-control groups. Perphenazine 76-88 prolactin Mus musculus 10-13 18462031-4 1998 However, TGFalpha mRNA expression was decreased by perphenazine. Perphenazine 51-63 transforming growth factor alpha Mus musculus 9-17 8689810-0 1996 Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Perphenazine 53-65 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 81-87 9435993-12 1997 As potent inhibitors of CYP2D6, both paroxetine and fluoxetine have the potential to increase the plasma concentrations of antipsychotic medications metabolised through this enzyme, including perphenazine, haloperidol, thioridazine and risperidone in patients who are CYP2D6 extensive metabolisers. Perphenazine 192-204 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 24-30 9333110-2 1997 Most classic antipsychotic agents such as perphenazine are metabolized by the CYP2D6 isozyme and are often coadministered with antidepressant agents. Perphenazine 42-54 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 78-84 9333110-3 1997 This study assessed the extent of changes in CYP2D6 isozyme activity in vivo after pretreatment with paroxetine and its consequences on perphenazine kinetics and central nervous system effects. Perphenazine 136-148 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 45-51 9333110-4 1997 METHODS: Eight extensive metabolizers for CYP2D6 were administered a single dose of perphenazine (0.11 mg/kg orally) or placebo following a randomized double-blind design. Perphenazine 84-96 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 42-48 9333110-10 1997 CONCLUSION: Coadministration of perphenazine after pretreatment with a standard therapeutic dose of paroxetine increased the plasma concentration and central nervous system side effects of perphenazine, primarily as a result of inhibition of the CYP2D6 isozyme. Perphenazine 32-44 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 246-252 8689810-1 1996 Steady-state serum concentration to dose ratios of the neuroleptic agent perphenazine were related to CYP2D6 metabolizer status for 96 psychiatric inpatients: 88 extensive metabolizers and eight poor metabolizers. Perphenazine 73-85 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 102-108 8530591-5 1995 To test these hypotheses, we examined PRL responsiveness to TRH and the dopamine antagonist, perphenazine (PZ), in patients with pituitary macroadenomas who had hypopituitarism and others with intact pituitary function (controls). Perphenazine 93-105 prolactin Homo sapiens 38-41 8612387-0 1996 The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Perphenazine 74-86 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-10 8612387-2 1996 This study evaluates the importance of the CYP2D6 genotype for the disposition of the neuroleptic agents perphenazine and zuclopenthixol. Perphenazine 105-117 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 43-49 8612387-6 1996 RESULTS: The CYP2D6 genotype significantly predicted the oral clearance of perphenazine and zuclopenthixol (p < 0.01 by multiple regression). Perphenazine 75-87 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 13-19 8612387-8 1996 CONCLUSION: The results show that the genotype for CYP2D6 is closely related to the oral clearances of perphenazine and zuclopenthixol. Perphenazine 103-115 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 51-57 7599048-5 1995 Treatment of these mice with perphenazine (dopamine antagonist) from 6 months of age or transplantation of pituitary glands under the renal capsule at 6 months of age markedly increased serum levels of prolactin and significantly suppressed the incidence of adenomatous nodules at 12 months of age. Perphenazine 29-41 prolactin Mus musculus 202-211 8851636-3 1995 We examined the PRL response to intravenous perphenazine (PZ) in 11 elderly patients with psychotic symptoms complicating either a major depression (MD-P) or a dementia. Perphenazine 44-56 prolactin Homo sapiens 16-19 1473523-8 1992 In vitro addition of perphenazine stimulated the release of prolactin by PHC but was without any effect on PI and (P-N). Perphenazine 21-33 prolactin Rattus norvegicus 60-69 7826496-3 1994 We examined the onset of NIP in 12 closely monitored, elderly psychiatric inpatients diagnosed with dementia being treated with perphenazine. Perphenazine 128-140 CDP-L-ribitol pyrophosphorylase A Homo sapiens 25-28 1357903-4 1992 In ovariectomized mice, prolyl endopeptidase activity was significantly higher in the uterus treated with progesterone or estradiol than in the uterus treated with vehicle oil only or a dopamine antagonist (perphenazine) which stimulates prolactin secretion. Perphenazine 207-219 prolyl endopeptidase Mus musculus 24-44 2310408-1 1990 The phenothiazines chlorpromazine and perphenazine and the butyrophenone haloperidol were shown to be reversible inhibitors of glutamate dehydrogenase (GDH). Perphenazine 38-50 glutamate dehydrogenase 1 Homo sapiens 127-150 2310408-1 1990 The phenothiazines chlorpromazine and perphenazine and the butyrophenone haloperidol were shown to be reversible inhibitors of glutamate dehydrogenase (GDH). Perphenazine 38-50 glutamate dehydrogenase 1 Homo sapiens 152-155 7053978-2 1982 Daily administration of 0.1 micrograms estradiol benzoate to female mice for 4 weeks significantly increased the amplitude of PRL release induced by perphenazine. Perphenazine 149-161 prolactin Mus musculus 126-129 2298188-5 1990 Perphenazine given orally (0.5 and 1.0 mg/kg bwt) increased plasma prolactin concentrations when measured 3 and 6 h following feeding (P less than 0.05). Perphenazine 0-12 prolactin Equus caballus 67-76 7053978-3 1982 A dose of 1.0 micrograms had no stimulatory effect, while doses of 10, 20, and 50 micrograms completely prevented the release of PRL in response to perphenazine. Perphenazine 148-160 prolactin Mus musculus 129-132 2781150-2 1989 Under the same experimental condition, the inverse relationship between the decrease of hepatic drug-metabolizing enzymes and delta-ALA synthetase activity and the increase of heme oxygenase activity was observed in perphenazine (PPZ)- or chlorpromazine (CPZ)-treated rats. Perphenazine 216-228 5'-aminolevulinate synthase 1 Rattus norvegicus 126-146 35527777-0 2022 Perphenazine and prochlorperazine decrease glioblastoma U-87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, E-cadherin, alpha-tubulin and integrins (alpha3, alpha5, and beta1) levels. Perphenazine 0-12 tubulin alpha 1b Homo sapiens 151-164 35527777-0 2022 Perphenazine and prochlorperazine decrease glioblastoma U-87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, E-cadherin, alpha-tubulin and integrins (alpha3, alpha5, and beta1) levels. Perphenazine 0-12 integrin subunit alpha 3 Homo sapiens 169-205 35527777-7 2022 The impact of perphenazine and prochlorperazine on the motility of human Uppsala 87 malignant glioma (U87-MG) cells was evaluated using a wound-healing assay, cellular migration and invasion were assessed by Transwell assay, and the protein expression levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins were determined by western blotting. Perphenazine 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 262-267 35527777-7 2022 The impact of perphenazine and prochlorperazine on the motility of human Uppsala 87 malignant glioma (U87-MG) cells was evaluated using a wound-healing assay, cellular migration and invasion were assessed by Transwell assay, and the protein expression levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins were determined by western blotting. Perphenazine 14-26 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 269-274 35527777-7 2022 The impact of perphenazine and prochlorperazine on the motility of human Uppsala 87 malignant glioma (U87-MG) cells was evaluated using a wound-healing assay, cellular migration and invasion were assessed by Transwell assay, and the protein expression levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins were determined by western blotting. Perphenazine 14-26 cadherin 1 Homo sapiens 276-286 35527777-7 2022 The impact of perphenazine and prochlorperazine on the motility of human Uppsala 87 malignant glioma (U87-MG) cells was evaluated using a wound-healing assay, cellular migration and invasion were assessed by Transwell assay, and the protein expression levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins were determined by western blotting. Perphenazine 14-26 tubulin alpha 1b Homo sapiens 288-301 35527777-8 2022 The present study explored the effects of perphenazine and prochlorperazine on the levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins (alpha3, alpha5, and beta1), as well as on the migratory and invasive ability of U87-MG cells. Perphenazine 42-54 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 35527777-8 2022 The present study explored the effects of perphenazine and prochlorperazine on the levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins (alpha3, alpha5, and beta1), as well as on the migratory and invasive ability of U87-MG cells. Perphenazine 42-54 tubulin alpha 1b Homo sapiens 119-132 35527777-8 2022 The present study explored the effects of perphenazine and prochlorperazine on the levels of ABCB1, ABCG2, E-cadherin, alpha-tubulin and integrins (alpha3, alpha5, and beta1), as well as on the migratory and invasive ability of U87-MG cells. Perphenazine 42-54 integrin subunit alpha 3 Homo sapiens 137-173 35527777-9 2022 The results suggested that perphenazine and prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells. Perphenazine 27-39 ATP binding cassette subfamily B member 1 Homo sapiens 145-150 35527777-9 2022 The results suggested that perphenazine and prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells. Perphenazine 27-39 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 165-170 35527777-9 2022 The results suggested that perphenazine and prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells. Perphenazine 27-39 cadherin 1 Homo sapiens 184-194 35527777-9 2022 The results suggested that perphenazine and prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, alpha-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells. Perphenazine 27-39 tubulin alpha 1b Homo sapiens 196-209 35527777-10 2022 In conclusion, the decrease in migratory and invasive ability following treatment with phenothiazine derivatives due to the increase in ABCG2 and E-cadherin expression, and decrease in alpha-tubulin and integrins expression, may suggest that research on perphenazine and prochlorperazine in the treatment of glioblastoma is worth continuing. Perphenazine 254-266 tubulin alpha 1b Homo sapiens 185-198 2781150-2 1989 Under the same experimental condition, the inverse relationship between the decrease of hepatic drug-metabolizing enzymes and delta-ALA synthetase activity and the increase of heme oxygenase activity was observed in perphenazine (PPZ)- or chlorpromazine (CPZ)-treated rats. Perphenazine 230-233 5'-aminolevulinate synthase 1 Rattus norvegicus 126-146 2808120-2 1989 Oral administration of the dopamine antagonist, perphenazine, led to a 5-10-fold elevation of serum prolactin after two days of treatment which was maintained for the 54 days of study. Perphenazine 48-60 prolactin Rattus norvegicus 100-109 3402388-3 1988 The band becomes markedly altered by stimuli known to influence PRL secretion, such as nursing, estradiol benzoate, and perphenazine. Perphenazine 120-132 prolactin Mus musculus 64-67 3795197-0 1986 Prolactin response to perphenazine. Perphenazine 22-34 prolactin Homo sapiens 0-9 2885243-1 1987 Ca2+ channel blocker (sensit) and calmodulin antagonists (thioridazine, perphenazine, oxyprothepine) applied to the mucosal side of frog urinary bladder, weakened the response of epithelial cells to vasopressin. Perphenazine 72-84 calmodulin 1 Homo sapiens 34-44 2885243-1 1987 Ca2+ channel blocker (sensit) and calmodulin antagonists (thioridazine, perphenazine, oxyprothepine) applied to the mucosal side of frog urinary bladder, weakened the response of epithelial cells to vasopressin. Perphenazine 72-84 arginine vasopressin Homo sapiens 199-210 3099198-5 1987 A significant decrease was seen, however, in basal and perphenazine-stimulated levels of prolactin after pregnancy in both the younger and older first-pregnancy groups but not in the controls. Perphenazine 55-67 prolactin Homo sapiens 89-98 3129769-1 1988 Repeated coadministration of amitriptyline (AMT) and perphenazine (PPZ) decreased the AMT-induced increase of hepatic microsomal aminopyrine N-demethylase, aniline hydroxylase, NADPH-cytochrome c reductase and UDP-glucuronyltransferase (UDP-GT) activities in rats. Perphenazine 53-65 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 210-235 3129769-1 1988 Repeated coadministration of amitriptyline (AMT) and perphenazine (PPZ) decreased the AMT-induced increase of hepatic microsomal aminopyrine N-demethylase, aniline hydroxylase, NADPH-cytochrome c reductase and UDP-glucuronyltransferase (UDP-GT) activities in rats. Perphenazine 53-65 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 237-243 3129769-1 1988 Repeated coadministration of amitriptyline (AMT) and perphenazine (PPZ) decreased the AMT-induced increase of hepatic microsomal aminopyrine N-demethylase, aniline hydroxylase, NADPH-cytochrome c reductase and UDP-glucuronyltransferase (UDP-GT) activities in rats. Perphenazine 67-70 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 210-235 3129769-1 1988 Repeated coadministration of amitriptyline (AMT) and perphenazine (PPZ) decreased the AMT-induced increase of hepatic microsomal aminopyrine N-demethylase, aniline hydroxylase, NADPH-cytochrome c reductase and UDP-glucuronyltransferase (UDP-GT) activities in rats. Perphenazine 67-70 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 237-243 3795197-3 1986 We compared serial prolactin levels following perphenazine stimulation in 20 women with histologically documented tumors to those in 22 normal controls. Perphenazine 46-58 prolactin Homo sapiens 19-28 3093797-5 1986 In one group (group I, n = 65), patients had greater than 100% rise in serum PRL following TRH or perphenazine (Pz) administration. Perphenazine 98-110 prolactin Homo sapiens 77-80 3717195-10 1986 For clinical testing, intramuscular perphenazine is preferred over oral perphenazine because of the shorter latency period and the higher PRL levels. Perphenazine 36-48 prolactin Homo sapiens 138-141 3717195-12 1986 This is the first report on the dynamic responses of PRL and blood pressure to intramuscular perphenazine in humans. Perphenazine 93-105 prolactin Homo sapiens 53-56 3930718-10 1985 LHRH challenge tests during perphenazine-induced hyperprolactinemia in rats indicated that prolactin may decrease pituitary sensitivity to LHRH. Perphenazine 28-40 gonadotropin releasing hormone 1 Rattus norvegicus 0-4 2993029-2 1985 Pharmacological manipulations of blood prolactin level, by perphenazine and bromocriptine, were used to stimulate or arrest tumor growth, respectively. Perphenazine 59-71 prolactin Rattus norvegicus 39-48 2993029-3 1985 During perphenazine treatment, a 2-3-fold increase in membranal tyrosine protein kinase activity, measured with angiotensin II as substrate, preceded the 3-4-fold increase in tumor area. Perphenazine 7-19 angiotensinogen Rattus norvegicus 112-126 2994657-1 1985 The calmodulin antagonists trifluoperazine, chlorpromazine, perphenazine, promazine, tamoxifen and the naphthalene sulfonamide derivatives W7 and W13 increased the level of 32P-incorporation into human platelet PIP and PIP2. Perphenazine 60-72 calmodulin 1 Homo sapiens 4-14 2994657-1 1985 The calmodulin antagonists trifluoperazine, chlorpromazine, perphenazine, promazine, tamoxifen and the naphthalene sulfonamide derivatives W7 and W13 increased the level of 32P-incorporation into human platelet PIP and PIP2. Perphenazine 60-72 prolactin induced protein Homo sapiens 211-214 3930718-10 1985 LHRH challenge tests during perphenazine-induced hyperprolactinemia in rats indicated that prolactin may decrease pituitary sensitivity to LHRH. Perphenazine 28-40 gonadotropin releasing hormone 1 Rattus norvegicus 139-143 3993313-3 1985 When, subsequent to litter removal, similar rats were injected with perphenazine, a significant increase of plasma Prl was observed. Perphenazine 68-80 prolactin Rattus norvegicus 115-118 6432976-10 1984 PRL secretion was examined following a provocative stimulus (perphenazine) in rats fed the experimental diets for 4 or 10-22 weeks. Perphenazine 61-73 prolactin Rattus norvegicus 0-3 4038736-7 1985 Another group of rats were fitted with jugular cannulae and treated with perphenazine, a potent prolactin-stimulating drug. Perphenazine 73-85 prolactin Rattus norvegicus 96-105 6432976-11 1984 Although perphenazine increased serum PRL and depleted the pituitary of PRL, differences in dietary lipid saturation caused no significant changes in these indices. Perphenazine 9-21 prolactin Rattus norvegicus 38-41 6432976-11 1984 Although perphenazine increased serum PRL and depleted the pituitary of PRL, differences in dietary lipid saturation caused no significant changes in these indices. Perphenazine 9-21 prolactin Rattus norvegicus 72-75 6723574-6 1984 However, treatments such as ovariectomy, ovariectomy plus estradiol benzoate, perphenazine, and 2-Br-alpha-ergocryptine affected the concentration of labeled cleaved PRL in the same manner as they did that of the intact molecule. Perphenazine 78-90 prolactin Rattus norvegicus 166-169 6709643-4 1984 Administration of 1 microgram of TP, the lowest dose tested, had no significant effects on basal serum PRL concentrations and only slightly inhibited the release of PRL induced by perphenazine, but the weight and PRL concentration of the pituitary gland were significantly depressed. Perphenazine 180-192 prolactin Mus musculus 165-168 6426097-2 1984 Prolactin induced by perphenazine administration significantly enhanced the activities of total TK or its isozyme in the tumors. Perphenazine 21-33 prolactin Rattus norvegicus 0-9 6709643-4 1984 Administration of 1 microgram of TP, the lowest dose tested, had no significant effects on basal serum PRL concentrations and only slightly inhibited the release of PRL induced by perphenazine, but the weight and PRL concentration of the pituitary gland were significantly depressed. Perphenazine 180-192 prolactin Mus musculus 165-168 6709643-5 1984 However, at doses of 10, 20, and 50 micrograms TP, perphenazine-induced PRL release, pituitary PRL concentration, and pituitary gland weight were all reduced in a dose-related manner. Perphenazine 51-63 prolactin Mus musculus 72-75 7189453-5 1980 Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. Perphenazine 0-12 prolactin Homo sapiens 51-60 6286107-4 1982 A similar effect was observed when rats were treated with perphenazine (to stimulate endogenous prolactin secretion) either alone or in combination with the antiestrogen tamoxifen. Perphenazine 58-70 prolactin Rattus norvegicus 96-105 7120089-0 1982 Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailability testing. Perphenazine 78-90 prolactin Homo sapiens 6-15 7202016-3 1982 The binding of calmodulin to fluphenazine, perphenazine and 7-aminotriflupromazine involved on the one hand non-specific electrostatic interactions which are abolished by increasing the eluent salt concentration, and on the other hand, Ca2+-dependent interactions which are reversed by EGTA addition. Perphenazine 43-55 calmodulin 1 Homo sapiens 15-25 7155994-5 1982 Perphenazine at both doses increased serum prolactin, but the increase was greater when 0.5 mg was administered. Perphenazine 0-12 prolactin Rattus norvegicus 43-52 7262630-5 1981 Median serum prolactin levels increased from 50 ng/ml in the controls to 570 ng/ml in the perphenazine treated animals and to 600 ng/ml in the pituitary transplanted rats-levels comparable with those seen in lactation (870 ng/ml). Perphenazine 90-102 prolactin Rattus norvegicus 13-22 6788061-2 1981 Perphenazine (Pz) produced a dose-related increase in plasma PRL, but stimulation of tumour growth in the absence of E2 required a minimal level of plasma PRL induced by Pz (0.15 mg/100 g body wt/day or more). Perphenazine 0-12 prolactin Rattus norvegicus 61-64 7428700-8 1980 Lactation, nursing, perphenazine injection, estradiol benzoate treatment, all stimuli that enhance PRL secretion, increased the proportion of little PRL in sera and abolished the strain difference existing in the nonlactating state. Perphenazine 20-32 prolactin Mus musculus 149-152 7430914-5 1980 While prolactin markedly proliferated and anti-prolactin serum significantly inhibited the mucosal weight, oestradiol, TRH and perphenazine dramatically depressed proliferation of the mucosa, suggesting that prolactin secretion was inhibited. Perphenazine 127-139 prolactin Homo sapiens 47-56 7430914-5 1980 While prolactin markedly proliferated and anti-prolactin serum significantly inhibited the mucosal weight, oestradiol, TRH and perphenazine dramatically depressed proliferation of the mucosa, suggesting that prolactin secretion was inhibited. Perphenazine 127-139 prolactin Homo sapiens 47-56 6770916-0 1980 Pituitary sensitivity to LHRH in hyperprolactinemia induced by perphenazine and renal pituitary transplants in female rats. Perphenazine 63-75 gonadotropin releasing hormone 1 Rattus norvegicus 25-29 782857-3 1976 Perphenazine-induced PRL release in normal mice and in GTG-injected non-obese mice was compared to that of GTG-injected obese mice after the initial development of obesity, after body weight reduction by diet control and after the resumption of obesity by ad lib. Perphenazine 0-12 prolactin Mus musculus 21-24 7374922-0 1980 Effect of perphenazine on secretory patterns of growth hormone in the rat. Perphenazine 10-22 gonadotropin releasing hormone receptor Rattus norvegicus 48-62 7374922-1 1980 A nonstressfull frequent sampling technique was employed to determine the effect of perphenazine, 5 mg/kg on spontaneous secretion of rat growth hormone (rGH). Perphenazine 84-96 gonadotropin releasing hormone receptor Rattus norvegicus 138-152 6446099-3 1980 The simultaneous administration of perphenazine (a dopaminergic neurone inhibitor) potentiates the adenohypophyseal and ceruloplasmin reaction, but does not modify the hypothalamic ascorbic acid reaction. Perphenazine 35-47 ceruloplasmin Rattus norvegicus 120-133 6446099-4 1980 Perphenazine combined with the thyroid hormones blocks the latters" inhibitory effect on the adenohypophyseal, ceruloplasmin and hypothalamic ascorbic acid reaction to oestradiol. Perphenazine 0-12 ceruloplasmin Rattus norvegicus 111-124 468103-6 1979 Integrated perphenazine-induced PRL responses were likewise similar during the 2 study periods: 101 +/- 16 ng . Perphenazine 11-23 prolactin Homo sapiens 32-35 579030-0 1977 Perphenazine-induced prolactin secretion in acromegaly. Perphenazine 0-12 prolactin Homo sapiens 21-30 528068-6 1979 The ratio of prolactin depleted from the pituitary gland to prolactin detected in serum after perphenazine injection, which reflected the metabolic clearance rate of prolactin, was highest in two strains with a high incidence of mammary tumors and relatively lower in low-tumor strains. Perphenazine 94-106 prolactin Mus musculus 13-22 528068-6 1979 The ratio of prolactin depleted from the pituitary gland to prolactin detected in serum after perphenazine injection, which reflected the metabolic clearance rate of prolactin, was highest in two strains with a high incidence of mammary tumors and relatively lower in low-tumor strains. Perphenazine 94-106 prolactin Mus musculus 60-69 528068-6 1979 The ratio of prolactin depleted from the pituitary gland to prolactin detected in serum after perphenazine injection, which reflected the metabolic clearance rate of prolactin, was highest in two strains with a high incidence of mammary tumors and relatively lower in low-tumor strains. Perphenazine 94-106 prolactin Mus musculus 60-69 702341-4 1978 An increase in spin-probe immobilization was induced by each drug with approximate relative potencies given by the order: desmethylchlorpromazine congruent to thioridazine congruent to fluphenazine congruent to prochlorperazine congruent to trifluoperazine greater than acetophenazine congruent to triflupromazine congruent to chlorpromazine greater than promazine greater than promethazine greater than perphenazine. Perphenazine 404-416 spindlin 1 Homo sapiens 15-19 711134-0 1978 Dynamic evaluation of prolactin secretion with perphenazine in normal and hyperprolactinemic subjects. Perphenazine 47-59 prolactin Homo sapiens 22-31 15719-6 1977 Withdrawal of perphenazine from rats bearing MTW9-P caused a fall to normal of plasma prolactin, no tumor regression, and no significant change in prolactin binding. Perphenazine 14-26 prolactin Rattus norvegicus 86-95 191182-2 1977 Following an oophorectomy-induced remission, perphenazine, which stimulates endogenous prolactin release, was able to restore tumor growth whether or not Tamoxifen was added. Perphenazine 45-57 prolactin Rattus norvegicus 87-96 191182-5 1977 In intact rats, after regression was obtained by daily administration of Tamoxifen and the prolactin inhibitor, lergotrile mesylate, perphenazine induced tumor growth when the latter was discontinued, even though Tamoxifen was continued for 50 days. Perphenazine 133-145 prolactin Rattus norvegicus 91-100 782857-5 1976 The GTG-injected mice which did not become obese had greater (50%) than normal levels of serum PRL following perphenazine stimulation in 2 of 3 experiments. Perphenazine 109-121 prolactin Mus musculus 95-98 782857-7 1976 Perphenazine-induced PRL levels in mice rendered obese with GTG were much greater (2-3 times higher than normal). Perphenazine 0-12 prolactin Mus musculus 21-24 32527541-6 2020 Annexin-V/PI double staining assay suggested that perphenazine could effectively induce ISK and KLE cell apoptosis. Perphenazine 50-62 annexin A5 Homo sapiens 0-9 3617-0 1976 Prolactin stimulation test with perphenazine: an evaluation of plasma prolactin levels and pituitary secretory activity in the rat. Perphenazine 32-44 prolactin Rattus norvegicus 0-9 3617-0 1976 Prolactin stimulation test with perphenazine: an evaluation of plasma prolactin levels and pituitary secretory activity in the rat. Perphenazine 32-44 prolactin Rattus norvegicus 70-79 3617-6 1976 The results obtained after perphenazine treatment in the latter group made it clear that the effect of oestrogen treatment on prolactin release can be completely blocked by increasing synthesis and/or release of the prolactin-release inhibiting factor (PIF). Perphenazine 27-39 prolactin Rattus norvegicus 126-135 3617-6 1976 The results obtained after perphenazine treatment in the latter group made it clear that the effect of oestrogen treatment on prolactin release can be completely blocked by increasing synthesis and/or release of the prolactin-release inhibiting factor (PIF). Perphenazine 27-39 prolactin Rattus norvegicus 216-225 3617-7 1976 Since perphenazine induces decrease of pituitary prolactin and a concomitant increase of plasma prolactin levels through lowered PIF-action, the positive effect of oestrogens on prolactin release (as observed in gonadectomized male and young female rats) apparently is caused by a different mode of action. Perphenazine 6-18 prolactin Rattus norvegicus 49-58 3617-7 1976 Since perphenazine induces decrease of pituitary prolactin and a concomitant increase of plasma prolactin levels through lowered PIF-action, the positive effect of oestrogens on prolactin release (as observed in gonadectomized male and young female rats) apparently is caused by a different mode of action. Perphenazine 6-18 prolactin Rattus norvegicus 96-105 826472-2 1976 The intravenous administration of 0.33 mg/kg body weight of perphenazine or 1.0 mug/kg body weight of TRH gave a greater release of prolactin than higher doses of perphenazine (1.0 mg/kg) or TRH) (3.4 mug/kg), respectively. Perphenazine 60-72 thyrotropin releasing hormone Macaca mulatta 191-194 1208573-4 1975 Perphenazine, alpha-methyltyrosine and estrogen enhanced the rate of PRL synthesis in intact rats. Perphenazine 0-12 prolactin Rattus norvegicus 69-72 1208573-6 1975 On the other hand, administration of T4 to THX rats receiving perphenazine, alpha-methyltyrosine or estrogen diminished the stimulatory influence of these treatments on PRL synthesis. Perphenazine 62-74 prolactin Rattus norvegicus 169-172 1237395-0 1975 Prolactin and growth hormone levels in different inbred strains of mice: patterns in association with estrous cycle, time of day, and perphenazine stimulation. Perphenazine 134-146 prolactin Mus musculus 0-9 1237395-4 1975 However, PRL concentrations in sera after perphenazine injection followed a pattern characteristic of the mammary tumor incidence rate of the strain: C3H/St and CBA/St--the two high-incidence strains--had lower levels of PRL; C57BL/St and BALB/cST--the two low-incidence strains--had higher levels; and DBA/2St--the medium-incidence strain--had an intermediate level. Perphenazine 42-54 prolactin Mus musculus 9-12 1123467-1 1975 The effects on lactation of perphenazine, a tranquillizer which increases the level of prolactin in the blood, have been studied in cows, goats, guinea-pigs and rabbits. Perphenazine 28-40 prolactin Bos taurus 87-96 5104494-0 1971 The effect of perphenazine on the level of prolactin in sheep blood. Perphenazine 14-26 prolactin Ovis aries 43-52 3617-7 1976 Since perphenazine induces decrease of pituitary prolactin and a concomitant increase of plasma prolactin levels through lowered PIF-action, the positive effect of oestrogens on prolactin release (as observed in gonadectomized male and young female rats) apparently is caused by a different mode of action. Perphenazine 6-18 prolactin Rattus norvegicus 96-105 1107014-4 1975 However, when the mice were challenged with perphenazine, a drug that causes prompt release of PRL, GTG and BPM-obese mice released 2-5 times as much PRL as did lean controls, suggesting an impairment in the hypothalamic control of PRL secretion in GTG/BPM-obese mice. Perphenazine 44-56 prolactin Mus musculus 95-98 1107014-4 1975 However, when the mice were challenged with perphenazine, a drug that causes prompt release of PRL, GTG and BPM-obese mice released 2-5 times as much PRL as did lean controls, suggesting an impairment in the hypothalamic control of PRL secretion in GTG/BPM-obese mice. Perphenazine 44-56 prolactin Mus musculus 150-153 1107014-4 1975 However, when the mice were challenged with perphenazine, a drug that causes prompt release of PRL, GTG and BPM-obese mice released 2-5 times as much PRL as did lean controls, suggesting an impairment in the hypothalamic control of PRL secretion in GTG/BPM-obese mice. Perphenazine 44-56 prolactin Mus musculus 150-153 1170564-0 1975 Ovarian responses to perphenazine-induced prolactin secretion in the rats: Effect of ovulation, stress, and steroids. Perphenazine 21-33 prolactin Rattus norvegicus 42-51 4419558-0 1974 The effect of perphenazine-induced serum prolactin response on estrogen-primed mammary tumor-host systems, 13762 and R-35 mammary adenocarcinomas. Perphenazine 14-26 prolactin Homo sapiens 41-50 4683266-0 1973 Effect of perphenazine on the secretion of prolactin in vivo and in vitro. Perphenazine 10-22 prolactin Homo sapiens 43-52 5138318-0 1971 Evidence of antagonism between prolactin and gonadotrophin secretion: effect of methalibure on perphenazine-induced prolactin secretion inovariectomized rats. Perphenazine 95-107 prolactin Rattus norvegicus 116-125 33118660-0 2021 Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Perphenazine 70-82 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 10-16 33118660-1 2021 AIMS: To investigate the impact of cytochrome P450 2D6 (CYP2D6) on dose-adjusted serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol in a therapeutic drug monitoring (TDM) cohort of psychiatric patients. Perphenazine 131-143 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 35-54 33118660-1 2021 AIMS: To investigate the impact of cytochrome P450 2D6 (CYP2D6) on dose-adjusted serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol in a therapeutic drug monitoring (TDM) cohort of psychiatric patients. Perphenazine 131-143 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 56-62 33118660-2 2021 We also especially studied the functional impact of CYP2D6*41 on dose-adjusted serum concentrations in the perphenazine-treated patients. Perphenazine 107-119 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 52-58 33118660-6 2021 RESULTS: Mean dose-adjusted serum concentrations of perphenazine (564 samples) were 3.9-fold and 1.6-fold higher in CYP2D6 PMs and IMs, respectively, compared with NMs (p<0.001 and p<0.01). Perphenazine 52-64 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 116-122 33118660-9 2021 In our data material, the genotype CYP2D6 *1/*41 appears to have a similar impact on dose-adjusted serum concentrations of perphenazine as *1/null (null = variant allele encoding no enzyme function). Perphenazine 123-135 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 35-41 33118660-10 2021 CONCLUSIONS: This study shows that CYP2D6 is important for the metabolism of perphenazine and zuclopenthixol, but not for haloperidol and flupentixol. Perphenazine 77-89 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 35-41 33376545-0 2021 Perphenazine exerts antitumor effects on HUT78 cells through Akt dephosphorylation by protein phosphatase 2A. Perphenazine 0-12 AKT serine/threonine kinase 1 Homo sapiens 61-64 33376545-0 2021 Perphenazine exerts antitumor effects on HUT78 cells through Akt dephosphorylation by protein phosphatase 2A. Perphenazine 0-12 protein phosphatase 2 phosphatase activator Homo sapiens 94-108 33376545-4 2021 Phenothiazine anti-psychotic perphenazine (PPZ) exerts antitumor effects by reactivating PP2A. Perphenazine 29-41 protein phosphatase 2 phosphatase activator Homo sapiens 89-93 33376545-4 2021 Phenothiazine anti-psychotic perphenazine (PPZ) exerts antitumor effects by reactivating PP2A. Perphenazine 43-46 protein phosphatase 2 phosphatase activator Homo sapiens 89-93 33376545-5 2021 The present study investigated the molecular mechanism underling the antitumor effects of PPZ in the neuroblastoma rat sarcoma oncogene (NRAS)-mutated Sezary syndrome cell line, HUT78. Perphenazine 90-93 NRAS proto-oncogene, GTPase Homo sapiens 101-135 33376545-6 2021 The results of the present study demonstrated that PPZ induced the dephosphorylation of Akt and ERK1/2, and triggered apoptosis in HUT78 cells. Perphenazine 51-54 AKT serine/threonine kinase 1 Homo sapiens 88-91 33376545-6 2021 The results of the present study demonstrated that PPZ induced the dephosphorylation of Akt and ERK1/2, and triggered apoptosis in HUT78 cells. Perphenazine 51-54 mitogen-activated protein kinase 3 Homo sapiens 96-102 33376545-7 2021 In addition, a PP2A inhibitor blocked the PPZ-mediated dephosphorylation of Akt but did not affect that of ERK1/2. Perphenazine 42-45 protein phosphatase 2 phosphatase activator Homo sapiens 15-19 33376545-7 2021 In addition, a PP2A inhibitor blocked the PPZ-mediated dephosphorylation of Akt but did not affect that of ERK1/2. Perphenazine 42-45 AKT serine/threonine kinase 1 Homo sapiens 76-79 32527541-7 2020 Moreover, results of western blot assay indicated perphenazine obviously inhibited the phosphorylation of Akt. Perphenazine 50-62 AKT serine/threonine kinase 1 Homo sapiens 106-109 31172223-0 2019 Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines. Perphenazine 25-37 chemokine like factor Homo sapiens 80-83 31172223-7 2019 In the present study, we explore the anticancer effect of perphenazine and prochlorperazine in human melanotic (COLO829) and amelanotic (C32) melanoma cells concluding that prochlorperazine inhibits cell viability in a concentration-dependent manner, impairs motility, and decreases tyrosinase and MITF amounts. Perphenazine 58-70 tyrosinase Homo sapiens 283-293 31172223-7 2019 In the present study, we explore the anticancer effect of perphenazine and prochlorperazine in human melanotic (COLO829) and amelanotic (C32) melanoma cells concluding that prochlorperazine inhibits cell viability in a concentration-dependent manner, impairs motility, and decreases tyrosinase and MITF amounts. Perphenazine 58-70 melanocyte inducing transcription factor Homo sapiens 298-302 25699237-7 2015 We review the mechanisms of functional PP2A activation by drugs such as fingolimod, forskolin, OP449, and perphenazine. Perphenazine 106-118 protein phosphatase 2 phosphatase activator Homo sapiens 39-43 29441946-4 2018 The calculated EC50 values for perphenazine (0.98 muM) and prochlorperazine (0.97 muM) are related to their toxic concentrations in human plasma. Perphenazine 31-43 latexin Homo sapiens 50-53 29441946-4 2018 The calculated EC50 values for perphenazine (0.98 muM) and prochlorperazine (0.97 muM) are related to their toxic concentrations in human plasma. Perphenazine 31-43 latexin Homo sapiens 82-85 29648716-5 2016 was calculated to be 1.24 and 2.76 muM for fluphenazine and perphenazine, respectively. Perphenazine 60-72 latexin Homo sapiens 35-38 29648716-6 2016 Fluphenazine in concentration of 1.0 muM and perphenazine in concentrations of 1.0 and 3.0 muM inhibied melanogenesis and decreased microphthalmia-associated transcription factor content. Perphenazine 45-57 latexin Homo sapiens 91-94 31383588-1 2019 Inspired by the cytotoxicity of perphenazine toward cancer cells and its ability to activate the serine/threonine protein phosphatase 2A (PP2A), we prepared series of ether-carbon linked analogs of a constrained synthetic sphingolipid analog 3, known for its cytotoxicity, nutrient transporter down-regulation and vacuolation properties, incorporating the tricyclic neuroleptics phenoxazine and phenothiazine to represent hybrid structures with possible synergistic cytotoxic activity. Perphenazine 32-44 protein phosphatase 2 phosphatase activator Homo sapiens 138-142 30382490-4 2019 METHODS: The effect of trifluperazine, chlorpromazine, perphenazine, thioridazine and promethazine on rat liver AOX was measured spectrophotometrically. Perphenazine 55-67 acyl-CoA oxidase 1 Rattus norvegicus 112-115 28697173-9 2017 Two tested ASM inhibitors, perphenazine and fluphenazine that are also clinically used as antipsychotics, were effective in inhibiting xenografted tumour growth. Perphenazine 27-39 sphingomyelin phosphodiesterase 1 Homo sapiens 11-14 27810903-7 2017 In glioblastoma tumors with NNMT expression, activation of PP2A can be accomplished by FDA approved perphenazine (PPZ), which is currently used to treat mood disorders such as schizophrenia, bipolar disorder, etc. Perphenazine 100-112 nicotinamide N-methyltransferase Homo sapiens 28-32 27810903-7 2017 In glioblastoma tumors with NNMT expression, activation of PP2A can be accomplished by FDA approved perphenazine (PPZ), which is currently used to treat mood disorders such as schizophrenia, bipolar disorder, etc. Perphenazine 100-112 protein phosphatase 2 phosphatase activator Homo sapiens 59-63 27150024-4 2016 Recently, it is reported that PPZ directly binds with scaffolding subunit of PP2A complex and exerts anti-tumor effects on human T cell acute lymphoblastic leukemia. Perphenazine 30-33 protein phosphatase 2 phosphatase activator Homo sapiens 77-81 27150024-12 2016 The present results for the first time revealed that PPZ induced canine lymphoma cells apoptosis through Akt dephosphorylation via PP2A activation. Perphenazine 53-56 protein phosphatase 2 phosphatase activator Homo sapiens 131-135 26319634-1 2015 The aim of the present study is to monitor the release of perphenazine (PPZ) from thin polymer films in real-time by the multi-parametric surface plasmon resonance method (MP-SPR). Perphenazine 58-70 sepiapterin reductase Homo sapiens 175-178 26319634-1 2015 The aim of the present study is to monitor the release of perphenazine (PPZ) from thin polymer films in real-time by the multi-parametric surface plasmon resonance method (MP-SPR). Perphenazine 72-75 sepiapterin reductase Homo sapiens 175-178 22805805-7 2012 In addition, beta-glucosidase activity and ginsenoside Rd content decreased by 36.0 and 29.2% respectively after a 72-h incubation in the presence of 0.05 mM Calmodulin (CaM) antagonist Perphenazine. Perphenazine 186-198 calmodulin 1 Homo sapiens 158-168 24401270-5 2014 Using ligand-affinity chromatography coupled with mass spectrometry, we identified protein phosphatase 2A (PP2A) as a perphenazine target. Perphenazine 118-130 protein phosphatase 2 phosphatase activator Homo sapiens 107-111 24401270-6 2014 T-ALL cell lines treated with perphenazine exhibited rapid dephosphorylation of multiple PP2A substrates and subsequent apoptosis. Perphenazine 30-42 protein phosphatase 2 phosphatase activator Homo sapiens 89-93 24401270-7 2014 Moreover, shRNA knockdown of specific PP2A subunits attenuated perphenazine activity, indicating that PP2A mediates the drug"s antileukemic activity. Perphenazine 63-75 protein phosphatase 2 phosphatase activator Homo sapiens 38-42 24401270-7 2014 Moreover, shRNA knockdown of specific PP2A subunits attenuated perphenazine activity, indicating that PP2A mediates the drug"s antileukemic activity. Perphenazine 63-75 protein phosphatase 2 phosphatase activator Homo sapiens 102-106 24401270-8 2014 Finally, human T-ALLs treated with perphenazine exhibited suppressed cell growth and dephosphorylation of PP2A targets in vitro and in vivo. Perphenazine 35-47 protein phosphatase 2 phosphatase activator Homo sapiens 106-110 22099638-7 2012 She started having RLS symptoms approximately four years after starting perphenazine. Perphenazine 72-84 RLS1 Homo sapiens 19-22 24596208-0 2014 Activation of PP2A by perphenazine induces apoptosis in T-ALL. Perphenazine 22-34 protein phosphatase 2 phosphatase activator Homo sapiens 14-18 23023763-1 2013 The rhodamine 6G(+) -perphenazine (Rhod 6G(+) -PPH) compound is formed in the ester-exchange reaction between -OH of PPH and -COOC2 H5 of Rhod 6G(+) . Perphenazine 16-33 enolase 1 Homo sapiens 47-50 23023763-1 2013 The rhodamine 6G(+) -perphenazine (Rhod 6G(+) -PPH) compound is formed in the ester-exchange reaction between -OH of PPH and -COOC2 H5 of Rhod 6G(+) . Perphenazine 16-33 enolase 1 Homo sapiens 117-120 23725509-2 2013 The purpose of this study was to investigate effects of D1/D2 dopamine receptors antagonist perphenazine on morphine analgesia and tolerance in rats. Perphenazine 92-104 dopamine receptor D2 Rattus norvegicus 56-80 23725509-7 2013 Obtained data suggested that D1/D2 dopamine receptors antagonist perphenazine was capable of suppressing opioid tolerance, possibly by the mechanism of inhibiting D2-dopamine receptor. Perphenazine 65-77 dopamine receptor D2 Rattus norvegicus 29-53 23725509-7 2013 Obtained data suggested that D1/D2 dopamine receptors antagonist perphenazine was capable of suppressing opioid tolerance, possibly by the mechanism of inhibiting D2-dopamine receptor. Perphenazine 65-77 dopamine receptor D2 Rattus norvegicus 163-183 23251210-5 2012 It is well known that terbinafine inhibits CYP2D6 and that perphenazine is metabolized mainly by CYP2D6. Perphenazine 59-71 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 97-103 22805805-7 2012 In addition, beta-glucosidase activity and ginsenoside Rd content decreased by 36.0 and 29.2% respectively after a 72-h incubation in the presence of 0.05 mM Calmodulin (CaM) antagonist Perphenazine. Perphenazine 186-198 calmodulin 1 Homo sapiens 170-173 21420906-3 2011 This contrasts with typical APDs, for example haloperidol and perphenazine, which are mainly DA D(2/)D(3) receptor antagonists and have weaker, if any, potency as 5-HT(2A) receptor antagonists. Perphenazine 62-74 5-hydroxytryptamine receptor 2A Homo sapiens 163-180 21420458-10 2011 We then evaluated the interaction of estrogens and neuroleptic agents (haloperidol and perphenazine) with the wild-type hGDH1 and hGDH2 and found that both inhibited hGDH2 more potently than hGDH1 and that the evolutionary Arg443Ser substitution was largely responsible for this sensitivity. Perphenazine 87-99 glutamate dehydrogenase 1 Homo sapiens 120-125 21420458-10 2011 We then evaluated the interaction of estrogens and neuroleptic agents (haloperidol and perphenazine) with the wild-type hGDH1 and hGDH2 and found that both inhibited hGDH2 more potently than hGDH1 and that the evolutionary Arg443Ser substitution was largely responsible for this sensitivity. Perphenazine 87-99 glutamate dehydrogenase 2 Homo sapiens 130-135 21420458-10 2011 We then evaluated the interaction of estrogens and neuroleptic agents (haloperidol and perphenazine) with the wild-type hGDH1 and hGDH2 and found that both inhibited hGDH2 more potently than hGDH1 and that the evolutionary Arg443Ser substitution was largely responsible for this sensitivity. Perphenazine 87-99 glutamate dehydrogenase 2 Homo sapiens 166-171 21420458-10 2011 We then evaluated the interaction of estrogens and neuroleptic agents (haloperidol and perphenazine) with the wild-type hGDH1 and hGDH2 and found that both inhibited hGDH2 more potently than hGDH1 and that the evolutionary Arg443Ser substitution was largely responsible for this sensitivity. Perphenazine 87-99 glutamate dehydrogenase 1 Homo sapiens 191-196 19666045-8 2009 Rofecoxib and celecoxib (both selective COX-2 inhibitors) also reversed the perphenazine-induced oxidative stress. Perphenazine 76-88 cytochrome c oxidase II, mitochondrial Rattus norvegicus 40-45 19640511-6 2009 Olanzapine was significantly different after baseline adjustment than perphenazine (p = .001) for E-selectin, and in those with low baseline CRP (<1 mg/L), olanzapine was significantly different than perphenazine (p < .001), risperidone (p < .001), and ziprasidone (p = .002) for CRP. Perphenazine 70-82 selectin E Homo sapiens 98-108 19640511-7 2009 Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant versus olanzapine (p = .010), quetiapine (p = .010), and risperidone (p = .006) after controlling for multiple comparisons. Perphenazine 0-12 intercellular adhesion molecule 1 Homo sapiens 36-42 19640511-7 2009 Perphenazine had the lowest 3-month ICAM-1 levels in subjects with baseline ICAM-1 above the median, but the differences were not statistically significant versus olanzapine (p = .010), quetiapine (p = .010), and risperidone (p = .006) after controlling for multiple comparisons. Perphenazine 0-12 intercellular adhesion molecule 1 Homo sapiens 76-82 20097249-7 2010 Aripiprazole, perphenazine, thioridazine, and fluoxetine were determined to be the potent hCES1 inhibitors. Perphenazine 14-26 carboxylesterase 1 Homo sapiens 90-95 17916903-7 2008 To test the hypothesis that reduced levels of the Prl signaling in mammary tissue partially contributed to the genetic resistance to mammary carcinogenesis, we used the neuroleptic drug, perphenazine, to transiently elevate serum Prl levels in the Cop strain. Perphenazine 187-199 prolactin Rattus norvegicus 50-53 19902987-7 2009 A number of clinical studies have indicated that there are significant relationships between the CYP2D6 genotype and steady-state concentrations of perphenazine, zuclopenthixol, risperidone and haloperidol. Perphenazine 148-160 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 97-103 19902987-10 2009 Therapeutic drug monitoring has been strongly recommended for many antipsychotics, including haloperidol, chlorpromazine, fluphenazine, perphenazine, risperidone and thioridazine, which are all metabolized by CYP2D6. Perphenazine 136-148 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 209-215 17916903-7 2008 To test the hypothesis that reduced levels of the Prl signaling in mammary tissue partially contributed to the genetic resistance to mammary carcinogenesis, we used the neuroleptic drug, perphenazine, to transiently elevate serum Prl levels in the Cop strain. Perphenazine 187-199 prolactin Rattus norvegicus 230-233 17429316-0 2007 CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Perphenazine 31-43 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 18075468-0 2007 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Perphenazine 113-125 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 18075468-0 2007 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Perphenazine 113-125 dopamine receptor D2 Homo sapiens 11-15 18075468-0 2007 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Perphenazine 113-125 prolactin Homo sapiens 91-100 18075468-1 2007 OBJECTIVES: We observed that CYP2D6 contributes to pharmacodynamic tissue sensitivity to perphenazine as measured by the areas under the curve (AUCs) expressed as a ratio (prolactin-AUC0-6/perphenazine-AUC0-6) in Chinese Canadians [Pharmacogenetics and Genomics 2007; 17:339-347]. Perphenazine 89-101 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 29-35 18075468-1 2007 OBJECTIVES: We observed that CYP2D6 contributes to pharmacodynamic tissue sensitivity to perphenazine as measured by the areas under the curve (AUCs) expressed as a ratio (prolactin-AUC0-6/perphenazine-AUC0-6) in Chinese Canadians [Pharmacogenetics and Genomics 2007; 17:339-347]. Perphenazine 89-101 prolactin Homo sapiens 172-181 18075468-1 2007 OBJECTIVES: We observed that CYP2D6 contributes to pharmacodynamic tissue sensitivity to perphenazine as measured by the areas under the curve (AUCs) expressed as a ratio (prolactin-AUC0-6/perphenazine-AUC0-6) in Chinese Canadians [Pharmacogenetics and Genomics 2007; 17:339-347]. Perphenazine 189-201 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 29-35 18075468-4 2007 RESULTS: After controlling for DRD2 polymorphisms, CYP2D6 was a significant predictor of pituitary pharmacodynamic tissue sensitivity to perphenazine (P=0.024; power=80.4%). Perphenazine 137-149 dopamine receptor D2 Homo sapiens 31-35 18075468-4 2007 RESULTS: After controlling for DRD2 polymorphisms, CYP2D6 was a significant predictor of pituitary pharmacodynamic tissue sensitivity to perphenazine (P=0.024; power=80.4%). Perphenazine 137-149 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 51-57 18075468-6 2007 A1/A1 genotype displayed a higher prolactin elevation 2 h after perphenazine administration (P=0.02). Perphenazine 64-76 prolactin Homo sapiens 34-43 18075468-8 2007 CONCLUSIONS: CYP2D6 seems to be an independent contributor to pituitary pharmacodynamic tissue sensitivity to perphenazine after accounting for DRD2 functional polymorphisms. Perphenazine 110-122 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 13-19 17429316-6 2007 We prospectively evaluated significance of CYP2D6 genetic variation for prolactin response to perphenazine (a model first-generation antipsychotic) in Asians. Perphenazine 94-106 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 43-49 17429316-9 2007 RESULTS: In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P<0.01). Perphenazine 97-109 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 28-34 17429316-9 2007 RESULTS: In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P<0.01). Perphenazine 97-109 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 38-44 17429316-9 2007 RESULTS: In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P<0.01). Perphenazine 97-109 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 38-44 17429316-10 2007 Notably, volunteers homozygous for CYP2D6*10 exhibited a significant reduction (66%) in mean pharmacodynamic tissue sensitivity as measured by the (prolactin-AUC0-6/perphenazine-AUC0-6) ratio (P=0.02). Perphenazine 165-177 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 35-41 17429316-11 2007 CONCLUSIONS: CYP2D6 genotype is a significant contributor to perphenazine concentration in Chinese-Canadians. Perphenazine 61-73 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 13-19 17429316-12 2007 Importantly, prolactin response, when normalized per unit perphenazine concentration, appears to be blunted in volunteers homozygous for CYP2D6*10. Perphenazine 58-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 137-143 17102980-10 2007 CONCLUSIONS: An association was observed between polymorphisms in HTR2A and HTR2C genes and occurrence of acute EPS in schizophrenic patients treated with perphenazine monotherapy. Perphenazine 155-167 5-hydroxytryptamine receptor 2A Homo sapiens 66-71 17102980-10 2007 CONCLUSIONS: An association was observed between polymorphisms in HTR2A and HTR2C genes and occurrence of acute EPS in schizophrenic patients treated with perphenazine monotherapy. Perphenazine 155-167 5-hydroxytryptamine receptor 2C Homo sapiens 76-81